The short answer
Pharmacologic niacin can weaken insulin glulisine’s glucose-lowering effect and worsen glucose control. This is different from claiming that ordinary food-level vitamin B3 causes the same risk.
What this answer covers
Oral niacin, especially pharmacologic nicotinic acid; dietary vitamin B3 and nicotinamide are different exposures.
- Supplement or preparation
- Niacin
- Medication ingredient
- insulin glulisine, human
Apidra names niacin
Apidra lists niacin among agents that may reduce its glucose-lowering effect. Closer glucose monitoring and clinician-directed treatment review may be needed.
Clinical evidence concerns a high-dose combination
A large vascular-risk trial of extended-release niacin plus laropiprant found more serious disturbances in diabetes control. It was not an glulisine-specific comparison, and laropiprant prevents attributing every outcome to niacin alone.
Dose and form matter
The trial concerned high-dose extended-release nicotinic acid with laropiprant. Its findings do not demonstrate the same risk from ordinary dietary vitamin B3 or every nicotinamide product.
Plan starting and stopping
Discuss pharmacologic niacin changes with the diabetes team and review glucose readings. No short spacing interval is established to prevent its systemic effect. Do not raise or lower insulin independently.
Evidence and practical considerations
Side effects & toxicity
Exact Apidra label name niacin as potentially weakening glucose lowering; narrowed to pharmacologic exposure and monitoring, without an exact adverse-event rate.
- Exact scope
- Oral niacin, especially pharmacologic nicotinic acid; dietary vitamin B3 and nicotinamide are different exposures. with Insulin glulisine human RxCUI400008 IN; Apidra product and routes.
- Medication form and route
- injected insulin glulisine; oral supplement
What remains uncertain
- No exact-pair event rate or universal insulin adjustment established.
Factors that may matter: Product; Dose; Meal pattern; Other glucose-active treatments.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People with diabetes prescribed Apidra
Hypoglycemia can be severe. Niacin may decrease glucose-lowering effect. Changed glucose-active treatment may require more monitoring and clinician-directed dose review. Subcutaneous mealtime injection within15minutes before or20minutes after meal start.
How this applies: Exact insulin glulisine product and routes independently checked.
General insulin risks do not establish an herb-specific adverse-event rate. Other insulins and premixes have different action and meal instructions.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25,673high-vascular-risk adults.
High-dose niacin-laropiprant increased serious disturbances in diabetes control compared with placebo.
How this applies: Indirect for exact insulin glulisine; source medication and supplement formulation are preserved.
Combination product, not ordinary nutritional niacin or a glipizide-specific estimate; no supplement need or protective spacing demonstrated. This does not establish an exact insulin-glulisine interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact glulisine article with independently inspected Apidra label and source-specific clinical limits. | |
| Research summary published |
Article revision: 9a3b69edf0039498
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.